Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

KemPharm, Inc. (KMPH)

5.81   -0.02 (-0.34%) 02-28 16:00
Open: 5.83 Pre. Close: 5.83
High: 5.97 Low: 5.79
Volume: 64,126 Market Cap: 200(M)

Technical analysis

as of: 2023-03-31 4:20:02 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 6.19     One year: 7.09
Support: Support1: 4.05    Support2: 3.36
Resistance: Resistance1: 5.3    Resistance2: 6.07
Pivot: 4.88
Moving Average: MA(5): 4.65     MA(20): 5.05
MA(100): 5.06     MA(250): 5.13
MACD: MACD(12,26): -0.3     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 32.1     %D(3): 30
RSI: RSI(14): 46
52-week: High: 6.92  Low: 4
Average Vol(K): 3-Month: 227 (K)  10-Days: 378 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ KMPH ] has closed above bottom band by 46.3%. Bollinger Bands are 108.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.02 - 5.04 5.04 - 5.05
Low: 4.65 - 4.67 4.67 - 4.69
Close: 4.77 - 4.8 4.8 - 4.83

Company Description

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077 which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. and Commave Therapeutics SA. The company was incorporated in 2006 and is headquartered in Celebration, Florida.

Headline News

Tue, 28 Feb 2023
Ergoteles LLC Has $761000 Stock Holdings in KemPharm, Inc ... - MarketBeat

Mon, 27 Feb 2023
KemPharm (KMPH) Files Preliminary Proxy -

Wed, 22 Feb 2023
KemPharm Announces Corporate Name Change to Zevra Therapeutics - Yahoo Finance

Tue, 31 Jan 2023
KemPharm Enhances Senior Management Team - GlobeNewswire

Tue, 24 Jan 2023
KemPharm Issues Letter to Shareholders - GlobeNewswire

Thu, 12 Jan 2023
KemPharm, Inc. (NASDAQ:KMPH): Are Analysts Optimistic? - Simply Wall St

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 35 (M)
Shares Float 31 (M)
% Held by Insiders 10.2 (%)
% Held by Institutions 19.7 (%)
Shares Short 1,370 (K)
Shares Short P.Month 1,550 (K)

Stock Financials

EPS -3.21
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -14.65
Profit Margin (%) 0
Operating Margin (%) -172
Return on Assets (ttm) -9
Return on Equity (ttm) -31.3
Qtrly Rev. Growth 46.2
Gross Profit (p.s.) 0.77
Sales Per Share 0.31
EBITDA (p.s.) -0.52
Qtrly Earnings Growth 0
Operating Cash Flow -15 (M)
Levered Free Cash Flow -11 (M)

Stock Valuations

PE Ratio -1.5
PEG Ratio 0
Price to Book value -0.33
Price to Sales 15.44
Price to Cash Flow -10.97

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2020-12-27
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.